Conditions: Vasomotor Symptoms; Hot Flashes
Keywords: Vasomotor symptoms; Hot Flashes; Menopause
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 103
Healthy volunteers: no

Brief summary:
The primary objective of this study was to evaluate the frequency of moderate to severe daily hot flashes 4 weeks after a single dose of erenumab (AMG 334) in women with hot flashes associated with menopause.

Detailed description:
This study will test the hypothesis that the vasodilation associated with capsaicin-induced dermal blood flow (DBF) provides a good model for the vasodilation associated with hot flashes; therefore erenumab doses that cause DBF inhibition will be safe and well tolerated, and will be effective in the reduction of the frequency and/or severity of HFs.

Arms:
arm 1: Participants received a single dose of placebo administered by subcutaneous injection. arm 2: Participants received a single dose of 70 mg erenumab administered by subcutaneous injection.

Interventions: intervention 1: Erenumab intervention 2: Placebo
Intervention descriptions: intervention 1: Administered via subcutaneous injection. intervention 2: Administered via subcutaneous injection

Protocol document: